Odyssey Therapeutics, Inc.
ODTX
$20.73
$0.010.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 19.85% | -- | |||
| Gross Profit | -23.77% | -- | |||
| SG&A Expenses | -20.49% | -7.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.57% | -15.10% | |||
| Operating Income | -10.00% | 11.46% | |||
| Income Before Tax | -28.13% | 0.25% | |||
| Income Tax Expenses | -126.67% | -55.00% | |||
| Earnings from Continuing Operations | -28.02% | 0.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.02% | 0.45% | |||
| EBIT | -10.00% | 11.46% | |||
| EBITDA | -10.85% | 11.51% | |||
| EPS Basic | 94.10% | 82.82% | |||
| Normalized Basic EPS | 95.14% | 85.04% | |||
| EPS Diluted | 94.10% | 82.82% | |||
| Normalized Diluted EPS | 95.14% | 85.04% | |||
| Average Basic Shares Outstanding | 2,069.31% | 479.42% | |||
| Average Diluted Shares Outstanding | 2,069.31% | 479.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||